- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19
- Blood sample
Population: General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antibiotics
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir
- Steroids
- Dexamethasone
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Steroids
- Vitamin D
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Community
- Primary care
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Monoclonal antibodies
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Statins
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Bamlanivimab/ Etesevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Monoclonal antibodies
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Community
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Remdesivir